SGH
MRTX

Sivik Global Healthcare’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Sivik Global Healthcare’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9,918
Closed -$1.46M – 60
2021
Q4 		$1.46M Buy
+9,918
New +$1.54M 0.62% 44
2021
Q3 		– Sell
-15,000
Closed -$2.42M – 60
2021
Q2 		$2.42M Buy
15,000
+5,000
+50% +$803K 0.47% 41
2021
Q1 		$1.71M Buy
+10,000
New +$1.98M 0.62% 44

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sivik Global Healthcare's MRTX Position: Q1 2022 in Review

Sivik Global Healthcare sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022, closing a stake of 9,918 shares — an estimated $1.46M sold.

Sivik Global Healthcare first reported a position in MRTX in Q1 2021 and held it in 3 quarters. The position peaked at $2.42M in Q2 2021. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

  • Sivik Global Healthcare reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Sivik Global Healthcare sold 9,918 Mirati Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1.46M.
  • Sivik Global Healthcare first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Sivik Global Healthcare's Mirati Therapeutics, Inc. Common Stock position peaked at $2.42M in Q2 2021.
  • 253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Sivik Global Healthcare's 13F filing for Q1 2022, filed 9 May 2022.